Related Experiment Video
Updated: Dec 17, 2025
07:50
Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
8.7K
NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma
Koray Yalcin1, Ercument Ovali2, Umut Ozdamarlar3
1Pediatric Hematology/Oncology and Stem Cell Transplantation Department, Medical Park Goztepe Hospital, Istanbul, Turkey.
International Cancer Conference Journal
|June 26, 2020
Summary
Relapsed/refractory Ewing sarcoma has a poor prognosis. Intratumoral injection of NK-92 cells offers a safe, novel treatment option with preliminary tumor response evidence in this challenging cancer.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Ewing sarcoma recurrence, particularly within two years, indicates a dire prognosis.
- Conventional treatments often fail for relapsed/refractory Ewing sarcoma, necessitating innovative therapeutic approaches.
Observation:
- A patient with relapsed/refractory Ewing sarcoma, unresponsive to standard therapies, underwent intratumoral NK-92 cell injections.
- Natural Killer (NK)-92 cells are an activated NK cell line known for potent cytotoxicity against cancer cells.
Findings:
- Intratumoral administration of NK-92 cells was well-tolerated, demonstrating no observable toxicity.
- The treatment showed preliminary evidence of tumor response in the treated relapsed/refractory Ewing sarcoma patient.
Implications:
- Intratumoral NK-92 cell injection represents a potentially safe and effective strategy for managing relapsed/refractory Ewing sarcoma.
- This approach warrants further investigation in clinical trials to establish its efficacy in a broader patient population.
